Cohance Lifesciences Limited — Others, 14-11-2024: Copy of Newspaper Publication

Suven Pharmaceuticals Limited has announced a board meeting to discuss its un-audited financial results for the quarter and half-year ended September 30, 2024. Key figures include total income from operations of ₹236.06 crore, with a net profit after tax of ₹76.33 crore for the quarter. The consolidated figures show total income from operations of ₹257.72 crore and a net profit after tax of ₹81.98 crore. This update reflects stable performance compared to the previous year, which may enhance investor confidence. Overall, the results signal potential for continued growth, presenting a positive outlook for shareholders.